PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

Drug Targets: Bile Acids in Motion

SBKB [doi:10.1038/sbkb.2014.218]
Featured Article - September 2014
Short description: Crystal structures of sodium-dependent bile acid transporters provide insight into transport mechanism.

Proposed mechanism of bile acid transport by ASBTs based on an alternating-access transport model. 1

Bile acids are cholesterol-based compounds that solubilize lipids, facilitating the uptake of dietary lipids and fat-soluble vitamins in the intestine. Bile acids are produced in the liver and released into the intestine; once the acids release their lipid cargoes, sodium-dependent bile acid transporters (ASBTs) mediate the cellular re-uptake of bile acids and their subsequent transport back to the liver. Blocking bile acid recycling can lower cholesterol levels, as new bile acids would need to be produced from cellular cholesterol pools. Thus, ASBT is a potential drug target to treat hypercholesterolemia and type 2 diabetes.

Substrate transport across the cellular membrane is thought to occur through an alternating-access mechanism: the transporter core has access to substrate on one side, and substrate binding to the transporter induces a conformational change, leading to a transporter opening on the alternate side and substrate release. A crystal structure of Neisseria meningitidis ASBT bound to two Na+ and taurocholic acid was previously solved in detergent: it captured the transporter in an inward-open conformation and revealed the substrate-binding site. However, definitive structural evidence for an alternating-access mechanism in ASBT was lacking.

Quick, Zhou and colleagues (PSI NYCOMPS) now report structural work on the ASBT homolog from the bacterium Yersinia frederiksenii, crystallized in a lipid environment. The crystal structures of substrate-free wild-type ASBT (PDB 4N7W) and a mutant unable to bind sodium (PDB 4N7X) assume inward- and outward-facing open conformations, respectively.

The structures show a dramatic difference in the relative arrangement of the transporter's panel and core regions. However, a narrow area within the core region containing highly conserved residues remains accessible in both conformations. Unexpectedly, the bile acid- binding site previously identified is only accessible in the inward-facing conformation, supporting an alternate binding site mechanism.

Based on structural and biochemical data, the authors propose that the binding of Na+ to ASBT is required for subsequent attachment of bile acid to the transporter's core, which leads to a conformational change from inward- to outward-facing states. The low sodium levels in the interior of the cell then trigger the release of sodium ions followed by the bile acid substrate.

Claudia Lupp

References

  1. X. Zhou et al. Structural basis of the alternating-access mechanism in a bile acid transporter.
    Nature. 505, 569-573 (2014). doi:10.1038/nature12811

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health